Omalizumabe no tratamento de urticária solar refratária aos anti-histamínicos: relato de caso e revisão da literatura
Omalizumab in the treatment of solar urticaria refractory to antihistamines: a case report and literature review
Bárbara Martins de Aquino; Alex Eustáquio de Lacerda; Inês Cristina Camelo Nunes; Luis Felipe Chiaverini Ensina
Resumo
A urticária solar é uma forma rara de urticária crônica induzida (UCInd). Os sintomas se iniciam minutos após a exposição ao sol e persistem por até 2 horas, interferindo nas atividades diárias do paciente, e consequentemente na sua qualidade de vida. O omalizumabe, anticorpo monoclonal anti-IgE já aprovado para o tratamento da urticária crônica espontânea, tem sido utilizado no tratamento das urticárias crônicas induzidas com boa resposta, inclusive na urticária solar. Neste artigo, relatamos um caso de urticária solar refratária aos anti-histaminicos, sua evolução após o uso do omalizumabe, e fazemos uma breve revisão da literatura sobre o tema.
Palavras-chave
Abstract
Solar urticaria is a rare form of chronic inducible urticaria. Symptoms start minutes after exposure to the sun and persist for up to 2 hours, interfering with the patients’ daily activities and, consequently, their quality of life. Omalizumab, a monoclonal anti-IgE antibody already approved for the treatment of chronic spontaneous urticaria, has been used in the treatment of chronic inducible urticaria, including solar urticaria, with good response. In this article, we report a case of solar urticaria refractory to antihistamines, show the patient’s evolution after the use of omalizumab, and briefly review the literature on the subject.
Keywords
Referências
1. Botto NC, Warshaw EM. Solar urticaria. J Am Acad Dermatol. 2008;59(6):909-22. doi:10.1016/j.jaad.2008.08.020.
2. Wright E, Kurland E, Lim HW. Solar urticaria caused by visible light in a 33-year-old male refractory to treatment with omalizumab. Photodermatol Photoimmunol Photomed. 2020;36(4):316-7. doi:10.1111/phpp.12545.
3. de Dios-Velázquez Á, González-de Arriba M, Beteta-Gorriti V, Macías E, Campanón-Toro V, Dávila I. Effectiveness of omalizumab in severe solar urticaria. Ann Allergy Asthma Immunol. 2016;116(3):260-2. doi:10.1016/j.anai.2015.12.023.
4. Snast I, Kremer N, Lapidoth M, Enk CD, Tal Y, Rosman Y, et al. Omalizumab for the Treatment of Solar Urticaria: Case Series and Systematic Review of the Literature. J Allergy Clin Immunol Pract. 2018 Jul-Aug;6(4):1198-1204.e3. doi: 10.1016/j.jaip.2018.02.032.
5. Zuberbier T, Aberer W, Asero R, Abdul Latiff AH, Baker D, BallmerWeber B, et al. The EAACI/GA²LEN/EDF/WAO guideline for the definition, classification, diagnosis and management of urticaria. Allergy. 2018;73(7):1393-414. doi: 10.1111/all.13397.
6. Maurer M, Fluhr JW, Khan DA. How to approach chronic inducible urticaria. J Allergy Clin Immunol Pract. 2018;6(4):1119-30. doi:10.1016/j.jaip.2018.03.007.
7. Chong WS, Khoo SW. Solar urticaria in Singapore: An uncommon photodermatosis seen in a tertiary dermatology center over a 10-year period. Photodermatol Photoimmunol Photomed. 2004;20:101‑4.
8. Harris BW, Badri T, Schlessinger J. Solar urticaria. StatPearls [Internet]. Disponível em: https://www.statpearls.com/ArticleLibrary/ viewarticle/30885.
9. Pérez-Ferriols A, Barnadas M, Gardeazábal J, de Argila D, Carrascosa JM, Aguilera P, et al. Solar urticaria: Epidemiology and clinical phenotypes in a Spanish series of 224 patients. Actas Dermosifiliogr. 2017;108(2):132-9.
10. Raigosa M, Toro Y, Sánchez J. Urticaria solar. Reporte de un caso y revisión de la literatura. Rev Alerg Mex. 2017;64(3):371‑5. doi:10.29262/ram.v64i3.202.
11. Beattie PE, Dawe RS, Ibbotson SH, Ferguson J. Characteristics and prognosis of idiopathic solar urticaria: a cohort of 87 cases. Arch Dermatol. 2003;139(9):1149-54. doi:10.1001/ archderm.139.9.1149.
12. Luther CA, Lim HW. Solar angioedema: A report of a patient and a review of literature. Photodermatol Photoimmunol Photomed. 2019;35(3):187-9. doi:10.1111/phpp.12445.
13. Kojima M, Horiko T, Nakamura Y, Aoki T. Solar urticaria. The relationship of photoallergen and action spectrum. Arch Dermatol. 1986;122(5):550-5. doi:10.1001/archderm.122.5.550.
14. Aguilera P. Inducing light tolerance with narrowband UV-B therapy in solar urticaria. Inducción de fototolerancia con ultravioleta B de banda estrecha en urticaria solar. Actas Dermosifiliogr. 2018;109(10):853. doi:10.1016/j.ad.2018.06.009.
15. Cardona V, Ansotegui IJ, Ebisawa M, El-Gamal Y, Fernandez Rivas M, Fineman S, et al. World allergy organization anaphylaxis guidance 2020. World Allergy Organ J [Internet]. 2020;13(10):100472. doi:10.1016/j.waojou.2020.10047. 16. Magerl M, Altrichter S, Borzova E, Giménez-Arnau A, Grattan CE, Lawlor F, et al. The definition, diagnostic testing, and management of chronic inducible urticarias - TheEAACI/GA(2) LEN/EDF/UNEV consensus recommendations 2016 update and revision. Allergy. 2016 Jun;71(6):780-2. ação grave após a intensa exposição solar e que apresentou controle rápido e duradouro com o uso de omalizumabe. No nosso conhecimento, este é o primeiro caso relatado no Brasil de tratamento eficaz de urticária solar com omalizumabe.
17. Junior SDD, Azizi GG, Sousa ACM, Lupi O, França AT, Valle SOR. Urticárias crônicas induzidas: atualização do tema. Arq Asma Alerg Imunol. 2020;4(3):305-16.
18. Levi A, Enk CD. Treatment of solar urticaria using antihistamine and leukotriene receptor antagonist combinations tailored to disease severity. Photodermatol Photoimmunol Photomed. 2015;31(6):302‑6. doi:10.1111/phpp.12186.
19. Okayama Y, Matsumoto H, Odajima H, Takahagi S, Hide M, Okubo K. Roles of omalizumab in various allergic diseases. Allergol Int. 2020;69(2):167-7. doi:10.1016/j.alit.2020.01.004.
20. Maurer M, Metz M, Brehler R, Hillen U, Jakob T, Mahler V, et al. Omalizumab treatment in patients with chronic inducible urticaria: A systematic review of published evidence. J Allergy Clin Immunol. 2018 Feb;141(2):638-49.
21. Güzelbey O, Ardelean E, Magerl M, Zuberbier T, Maurer M, Metz M. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy. 2008;63(11):1563-5. doi:10.1111/j.1398- 9995.2008.01879.x.
22. Waibel KH, Reese DA, Hamilton RG, Devillez RL. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol. 2010;125(2):490-91. doi:10.1016/j.jaci.2009.11.007.
23. Metz M, Altrichter S, Ardelean E, Kessler B, Krause K, Magerl M, et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol. 2011;154(2):177-80. doi: 10.1159/000320233.
24. Duchini G, Bäumler W, Bircher AJ, Scherer K. Failure of omalizumab (Xolair®) in the treatment of a case of solar urticaria caused by ultraviolet A and visible light. Photodermatol Photoimmunol Photomed. 2011;27(6):336-7. doi:10.1111/j.1600-0781.2011.00624.x.
25. Metz M, Ohanyan T, Church MK, Maurer M. Omalizumab is an effective and rapidly acting therapy in difficult-to-treat chronic urticaria: a retrospective clinical analysis. J Dermatol Sci. 2014;73(1):57-62. doi:10.1016/j.jdermsci.2013.08.011.
26. Levi A, Tal Y, Dranitzki Z, Shalit M, Enk CD. Successful omalizumab treatment of severe solar urticaria in a 6-year-old child. Pediatr Allergy Immunol. 2015;26(6):588-90. doi:10.1111/pai.12441.
27. Arasi S, Crisafulli G, Caminiti L, Guarneri F, Aversa T, Porcaro F, et al. Treatment with omalizumab in a 16-year-old Caucasian girl with refractory solar urticaria. Pediatr Allergy Immunol. 2015;26(6):583-5. doi: 10.1111/pai.12413.
28. Müller S, Schempp CM, Jakob T. Failure of omalizumab in the treatment of solar urticaria. J Eur Acad Dermatol Venereol. 2016;30(3):524-5. doi:10.1111/jdv.12922.
29. Terrani I, Bircher AJ, Scherer Hofmeier K. Solar urticaria induced by visible light: successful treatment with omalizumab. Clin Exp Dermatol. 2016;41(8):890-2. doi:10.1111/ced.12951.
30. Moncourier M, Assikar S, Matei I, Souyri N, Couture M, Rigot E, et al. Visible light-induced solar urticaria is improved by omalizumab. Photodermatol Photoimmunol Photomed. 2016 Sep;32(5-6):314‑16. doi: 10.1111/phpp.12271.
31. Ghazanfar MN, Sand C, Thomsen SF. Effectiveness and safety of omalizumab in chronic spontaneous or inducible urticaria: evaluation of 154 patients. Br J Dermatol. 2016;175(2):404-6. doi:10.1111/ bjd.14540.
32. Brüning JH, Ziemer M, Pemler S, Simon JC, Treudler R. Successful treatment of solar urticaria with omalizumab. J Dtsch Dermatol Ges. 2016;14(9):936-7. doi:10.1111/ddg.13017.
33. Baliu-Piqué C, Aguilera Peiró P. Three cases of solar urticaria successfully treated with omalizumab. J Eur Acad Dermatol Venereol. 2016;30(4):704-6. doi:10.1111/jdv.13001.
34. Kowalzick L, Thiel W, C Bielfeld, Ziegler H, Eickenscheidt L. Partielles Ansprechen einer Lichturtikaria auf Omalizumab [Partial response of solar urticaria to omalizumab therapy]. Hautarzt. 2017;68(6):492‑6. doi:10.1007/s00105-016-3913-0.
35. Aubin F, Avenel-Audran M, Jeanmougin M, Adamski H, Peyron JL, Marguery MC, et al. Omalizumab in patients with severe and refractory solar urticaria: A phase II multicentric study. J Am Acad Dermatol. 2016 Mar;74(3):574-5. doi: 10.1016/j.jaad.2015.11.021.
36. Combalia A, Fernández-Sartorio C, Aguilera P. Refractory solar urticaria successfully treated with omalizumab with normalization of phototest. Actas Dermosifiliogr. 2017;108(6):593-4. doi:10.1016/j.ad.2016.11.015.
37. Martinis M, Sirufo MM, Ginaldi L. Solar urticaria, a disease with many dark sides: is omalizumab the right therapeutic response? Reflections from a clinical case report. Open Med (Wars). 2019;14:403-406. doi:10.1515/med-2019-0042.
38. Kieselova K, Santiago F, Henrique M. Incapacitating solar urticaria: successful treatment with omalizumab. An Bras Dermatol. 2019;94(3):331-3. doi:10.1590/abd1806-4841.20198109.
39. Schaffenburg WC, Guerrero KT, Marks SN. Solar urticaria treated with omalizumab. Cutis. 2019;104(1):E4-E5.
40. Snast I, Lapidoth M, Uvaidov V, Enk CD, Mazor S, Hodak E, et al. Real-life experience in the treatment of solar urticaria: retrospective cohort study. Clin Exp Dermatol. 2019 Jul;44(5):e164-e170. doi: 10.1111/ced.13960.
41. Morgado-Carrasco D, Giácaman-Von der Weth M, Fustá-Novell X, Podlipnik S, Pérez-Ferriols A, Aguilera P. Clinical response and long-term follow-up of 20 patients with refractory solar urticaria under treatment with omalizumab. J Am Acad Dermatol. 2019:S0190- 9622(19)30874-6. doi: 10.1016/j.jaad.2019.05.070.
42. Vollono L, Bianchi L, Piccolo A, Mazzilli S, Campione E, Diluvio L. Good things come to those who wait: Successful response of solar urticaria to omalizumab after 1 year of treatment. Photodermatol Photoimmunol Photomed. 2020;10.1111/phpp.12577. doi:10.1111/phpp.12577.
Submetido em:
05/04/2020
Aceito em:
04/06/2021
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email